Literature DB >> 30030416

Preoperative Predictors of Death and Sustained Ventricular Tachycardia After Pulmonary Valve Replacement in Patients With Repaired Tetralogy of Fallot Enrolled in the INDICATOR Cohort.

Tal Geva1, Barbara Mulder2, Kimberlee Gauvreau1, Sonya V Babu-Narayan3, Rachel M Wald4, Kelsey Hickey1, Andrew J Powell1, Michael A Gatzoulis3, Anne Marie Valente1.   

Abstract

BACKGROUND: Risk factors for adverse clinical outcomes have been identified in patients with repaired tetralogy of Fallot before pulmonary valve replacement (PVR). However, pre-PVR predictors for post-PVR sustained ventricular tachycardia and death have not been identified.
METHODS: Patients with repaired tetralogy of Fallot enrolled in the INDICATOR cohort (International Multicenter TOF Registry), a 4-center international cohort study, who had a comprehensive preoperative evaluation and subsequently underwent PVR were included. Preprocedural clinical, ECG, cardiovascular magnetic resonance, and postoperative outcome data were analyzed. Cox proportional hazards multivariable regression analysis was used to evaluate factors associated with time from pre-PVR cardiovascular magnetic resonance until the primary outcome: death, aborted sudden cardiac death, or sustained ventricular tachycardia.
RESULTS: Of the 452 eligible patients (median age at PVR, 25.8 years), 36 (8%) reached the primary outcome (27 deaths, 2 resuscitated death, and 7 sustained ventricular tachycardia) at a median time after PVR of 6.5 years. Cox proportional hazards regression identified pre-PVR right ventricular ejection fraction <40% (hazard ratio, 2.39; 95% CI, 1.18-4.85; P=0.02), right ventricular mass-to-volume ratio ≥0.45 g/mL (hazard ratio, 4.08; 95% CI, 1.57-10.6; P=0.004), and age at PVR ≥28 years (hazard ratio, 3.10; 95% CI, 1.42-6.78; P=0.005) as outcome predictors. In a subgroup analysis of 230 patients with Doppler data, predicted right ventricular systolic pressure ≥40 mm Hg was associated with the primary outcome (hazard ratio, 3.42; 95% CI, 1.09-10.7; P=0.04). Preoperative predictors of a composite secondary outcome, postoperative arrhythmias and heart failure, included older age at PVR, pre-PVR atrial tachyarrhythmias, and a higher left ventricular end-systolic volume index.
CONCLUSIONS: In this observational investigation of patients with repaired tetralogy of Fallot, an older age at PVR and pre-PVR right ventricular hypertrophy and dysfunction were predictive of a shorter time to postoperative death and sustained ventricular tachycardia. These findings may inform the timing of PVR if confirmed by prospective clinical trials.

Entities:  

Keywords:  hypertrophy, right ventricular; pulmonary valve; risk factors; tachycardia, ventricular; tetralogy of Fallot; treatment outcome

Mesh:

Year:  2018        PMID: 30030416     DOI: 10.1161/CIRCULATIONAHA.118.034740

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

1.  QRS Duration During Follow-Up of Tetralogy of Fallot: How Valuable is it? Analysis of ECG Changes in Relation to Pulmonary Valve Implantation.

Authors:  Thomas Martens; Katrien François; Hans De Wilde; Laurence Campens; Laurent Demulier; Julie De Backer; Daniel Dewolf; Thierry Bove
Journal:  Pediatr Cardiol       Date:  2021-05-07       Impact factor: 1.655

Review 2.  The value of myocardial strain imaging in the evaluation of patients with repaired Tetralogy of Fallot: a review of the literature.

Authors:  Panagiotis Zachos; Vasilios Nevras; Nikias Milaras; Maria Karakosta; Alkistis Kalesi; Nearchos Kasinos; Antonios Destounis; Nikolaos L Kelekis; Ignatios Ikonomidis; Dimitrios Niakas
Journal:  Heart Fail Rev       Date:  2022-03-14       Impact factor: 4.214

3.  Statistical shape modeling reveals the link between right ventricular shape, hemodynamic force, and myocardial function in patients with repaired tetralogy of Fallot.

Authors:  Sarah Kollar; Elias Balaras; Laura J Olivieri; Yue-Hin Loke; Francesco Capuano
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-07-15       Impact factor: 5.125

4.  Abnormal Pulmonary Arterial Elastance Is Associated With Reduced Exercise Capacity in Tetralogy of Fallot.

Authors:  Alexander C Egbe; Nandan S Anavekar; Heidi M Connolly
Journal:  J Am Heart Assoc       Date:  2019-06-11       Impact factor: 5.501

5.  Pathophysiologic and Prognostic Implications of Right Atrial Hypertension in Adults With Tetralogy of Fallot.

Authors:  Alexander C Egbe; Crystal Bonnichsen; Yogesh N V Reddy; Jason H Anderson; Barry A Borlaug
Journal:  J Am Heart Assoc       Date:  2019-11-08       Impact factor: 5.501

6.  The applications and potential limitations of right ventricular volumes as surrogate marker in tetralogy of fallot.

Authors:  Alexander C Egbe; Keerthana Banala; Rahul Vojjini; Karim Osman; Arslan Afzal; Vaibhav Jain; Sahith Thotamgari; Naser M Ammash
Journal:  Int J Cardiol Heart Vasc       Date:  2019-11-14

7.  Modified Ventricular Global Function Index Correlates With Exercise Capacity in Repaired Tetralogy of Fallot.

Authors:  Hieu T Ta; Paul J Critser; Tarek Alsaied; Joshua Germann; Adam W Powell; Andrew N Redington; Justin T Tretter
Journal:  J Am Heart Assoc       Date:  2020-07-07       Impact factor: 5.501

8.  β2-Adrenoceptors and GRK2 as Potential Biomarkers in Patients With Chronic Pulmonary Regurgitation.

Authors:  María Rodriguez-Serrano; Joaquín Rueda; Francisco Buendía; Fermi Monto; Jaime Aguero; Ana Osa; Oscar Cano; Luis Martínez-Dolz; Pilar D'Ocon
Journal:  Front Pharmacol       Date:  2019-02-19       Impact factor: 5.810

9.  Impact of Inferior Venae Cava Assessment in Tetralogy of Fallot.

Authors:  Alexander C Egbe; Rahul Vojjini; Patricia A Pellikka; Crystal Bonnichsen; Jason H Anderson; Nathaniel W Taggart
Journal:  CJC Open       Date:  2020-02-24

10.  Prognostic Implications of Left Ventricular Cardiomyopathy in Adults With Tetralogy of Fallot.

Authors:  Alexander C Egbe; Patricia A Pellikka; Arslan Afzal; Vaibhav Jain; Sahith Thotamgari; William R Miranda; Heidi M Connolly
Journal:  CJC Open       Date:  2019-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.